BioTheryX receives IND clearance from FDA to proceed with Ph1 Study of BTX-1188

Clinical Impact
Written By Frances Benson

https://biotheryx.com/biotheryx-receives-ind-clearance-from-fda-to-proceed-with-phase-1-study-of-btx-1188-a-molecular-glue-for-the-treatment-of-hematologic-and-solid-malignancies/

Frances Benson
Previous

Tranquis Therapeutics presents positive preclinical data on TQS-168 for the treatment of ALS
Next

Palleon Pharmaceuticals appoints David Johnson to its Board of Directors